

[Fig. 1]




	RT	Area	% Area	EP Plate Count	Resolution	Symmetry Factor
1	6.93	16521	2.21	1896		
2	7.87	731336	97.79	3657	1.6	1.1


[Fig. 2]




[Fig. 3]


T47D
(Set 1&2, N=4)
Viability (%)
Concentration (nM)
MMAE
PBX7016
Teli-7016
Teli-Camp
Teli-MMAE
P63-7016


[Fig. 4]


SNU-5
(Set 1&2, N=4)
Viability (%)
Concentration (nM)
MMAE
PBX7016
Teli-7016
Teli-Camp
Teli-MMAE
P63-7016


[Fig. 5]


H1573
(Set 1&2,N=4)
Viability (%)
Concentration (nM)
MMAE
PBX7016
Teli-7016
Teli-Camp
Teli-MMAE
P63-7016


[Fig. 6]


HT29
(Set 1&2, N=4)
Viability (%)
Concentration (nM)
MMAE
PBX7016
Teli-7016
Teli-Camp
Teli-MMAE
P63-7016


[Fig. 7]


H1975
(Set 1&2, N=4)
Viability (%)
Concentration (nM)
MMAE
PBX7016
Teli-7016
Teli-Camp
Teli-MMAE
P63-7016


[Fig. 8]


OD (450-640 nm)
M01 antibody (nM)
Human
Cynomolgus
Rat
Mouse
Canine


[Fig. 9]


A
human c-Met
OD (450-640 nm)
Concentration (nM)
M01 antibody
M01-PBX-7016
B
cynomolgus c-Met
OD (450-640 nm)
Concentration (nM)
M01 antibody
M01-PBX-7016


[Fig. 10]


OD (450-650 nm)
2.5
2.0
1.5
1.2
0.9
0.6
0.3
0.0
0.001
0.01
0.1
1
10
100
Concentration (nM)
SNU-5
SNU-620
Hs746T
NCI-H1573
MKN-45
SNU-16
HT-29
NCI-H1975
SNU-1


[Fig. 11]


Body Weight Change (%)
20
10
0
-10
0
7
14
21
28
Days
P23, 3mg/kg
M01, 3mg/kg
P23-PBX-7016, 0.3mg/kg
P23-PBX-7016, 1mg/kg
P23-PBX-7016, 3mg/kg
M01-PBX-7016, 0.3mg/kg
M01-PBX-7016, 1mg/kg
M01-PBX-7016, 3mg/kg
M01-MMAE, 0.3mg/kg
M01-MMAE, 1mg/kg
M01-MMAE, 3mg/kg


[Fig. 12]


Tumor volume (mm3)
4000
3000
2000
1000
0
0
7
14
21
28
Days
P23, 3mg/kg
M01, 3mg/kg
P23-PBX-7016, 0.3mg/kg
P23-PBX-7016, 1mg/kg
P23-PBX-7016, 3mg/kg
M01-PBX-7016, 0.3mg/kg
M01-PBX-7016, 1mg/kg
M01-PBX-7016, 3mg/kg
M01-MMAE, 0.3mg/kg
M01-MMAE, 1mg/kg
M01-MMAE, 3mg/kg


[Fig. 13]


Tumor volume (mm3)
2000
1500
1000
500
0
0
2
4
6
8
10
12
14
Days
P23, 3mg/kg
M01, 3mg/kg
P23-PBX-7016, 0.3mg/kg
P23-PBX-7016, 1mg/kg
P23-PBX-7016, 3mg/kg
M01-PBX-7016, 0.3mg/kg
M01-PBX-7016, 1mg/
M01-PBX-7016, 3mg/kg
M01-MMAE, 0.3mg/kg
M01-MMAE, 1mg/kg
M01-MMAE, 3mg/kg


[Fig. 14]


Body Weight Change (%)
20
10
0
-10
-20
0
7
14
21
28
35
Days
P23, 10 mg/kg
M01, 10 mg/kg
P23-PBX-7016, 10 mg/kg
M01-MMAE, 1 mg/kg
M01-MMAE, 3 mg/kg
M01-MMAE, 10 mg/kg
M01-PBX-7016, 1 mg/kg
M01-PBX-7016, 3 mg/kg
M01-PBX-7016, 10 mg/kg


[Fig. 15]


Tumor volume (mm3)
2000
1600
1200
800
400
0
0
7
14
21
28
35
Days
P23, 10 mg/kg
M01, 10 mg/kg
P23-PBX-7016, 10 mg/kg
M01-MMAE, 1 mg/kg
M01-MMAE, 3 mg/kg
M01-MMAE, 10 mg/kg
M01-PBX-7016, 1 mg/kg
M01-PBX-7016, 3 mg/kg
M01-PBX-7016, 10 mg/kg

[Fig. 16]


Body Weight Change (%)
20
10
0
-10
-20
0
7
14
21
28
35
Days
P23, 3mg/kg, IV
M01, 3mg/kg
P23-MMAE, 3mg/kg
P23-PBX-7016, 3mg/kg
M01-MMAE, 0.3mg/kg
M01-MMAE, 1mg/kg
M01-MMAE, 3mg/kg
M01-PBX-7016, 0.3mg/kg
M01-PBX-7016, 1mg/kg
M01-PBX-7016, 3mg/kg

[Fig. 17]


Tumor volume (mm3)
2000
1500
1000
500
0
0
7
14
21
28
35
Days
P23, 3mg/kg
M01, 3mg/kg
P23-MMAE, 3mg/kg
P23-PBX-7016, 3mg/kg
M01-MMAE, 0.3mg/kg
M01-MMAE, 1mg/kg
M01-MMAE, 3mg/kg
M01-PBX-7016, 0.3mg/kg
M01-PBX-7016, 1mg/kg
M01-PBX-7016, 3mg/kg